Clinical Trial

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-11.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07077512
Lead Sponsor Sun Yat-sen University
Collaborators: Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Overseas Chinese Hospital,Guangdong
Conditions Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
Enrollment 30 participants
Start Date 2025-09-15
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-21